A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast Cancer
Margaret E. Gatti‐Mays(National Cancer Institute), Jung Min Lee(Kyung Hee University), Jane B. Trepel(National Institutes of Health), Jayakumar R. Nair(National Cancer Institute), Min-Jung Lee(National Institutes of Health), Akira Yuno(National Institutes of Health), Fatima Karzai(National Institutes of Health), Sanaz Soltani(National Institutes of Health), Ann McCoy(National Institutes of Health), Alexandra S. Zimmer(Johns Hopkins University), Stanley Lipkowitz(Center for Cancer Research), Jeffrey E. Green(Northwestern University)
Cited by 59
Related Papers
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
|Genome biology|2007|1.3k
Precisely printable and biocompatible silk fibroin bioink for digital light processing 3D printing
|Nature Communications|2018|964
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
|The Journal of Clinical Endocrinology & Metabolism|2003|650